CoChat

Comparison of the Metabolic Profiles Associated with Protonitazene and Protonitazepyne in Two Severe Poisonings

Open access

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Nitazenes represent an emerging class of new synthetic opioids characterized by a high-potency μ-opioid receptor (MOR) agonist activity. Background: We report two 20-year-old males who presented with severe neurorespiratory depression with typical opioid syndrome, but no opioid identification based on routine blood and urine screening tests. The first patient recovered with supportive care, mechanical ventilation, and naloxone infusion, whereas the second patient developed post-anoxic cardiac arrest and died from brain death. Methods: A complementary comprehensive toxicological screening using liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS) was performed, and data were processed using a dedicated molecular network strategy to profile the metabolites. Results: Protonitazene and protonitazepyne, two nitazenes differing in their ethylamine moieties (i.e., a diethyl versus a pyrrolidine substitution, respectively), were identified. We found an extensive metabolism of protonitazene, leading to the identification of multiple phase I (resulting from hydroxylation, N-desethylation, and O-despropylation) and phase II (resulting from glucuronidation) metabolites. By contrast, protonitazepyne metabolism appeared limited, with one metabolite annotated confidently, protonitazepyne acid, which resulted from the oxidative pyrrolidine ring cleavage. Concusions: To conclude, nitazene detection is highly challenging due to its extensive structural and metabolic diversity. Our findings highlight the contribution of the untargeted LC-HRMS screening approach and suggest that diagnostic product ions can serve as robust markers for nitazene identification.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/metabo15060371

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Chemical structure of (A) protonitazene and (B) protonitazepyne.
Figure 1 Chemical structure of (A) protonitazene and (B) protonitazepyne.CC BY · PubMed Central
Figure 2 Analytical features of protonitazene. (A) Extracted ion chromatogram at m/z 411.2391 corresponding to the [M + H]+ ion of protonitazene from LC-HRMS data obtained following the analysis of plasma extract. (B) Experimental isotopic pattern of protonitazene and (C) MS/MS spectra of the [M + H]+ ion of protonitazene.
Figure 2 Analytical features of protonitazene. (A) Extracted ion chromatogram at m/z 411.2391 corresponding to the [M + H]+ ion of protonitazene from LC-HRMS data obtained following the analysis of plasma extract. (B) Experimental isotopic pattern of protonitazene and (C) MS/MS spectra of the [M + H]+ ion of protonitazene.CC BY · PubMed Central
Figure 3 Analytical features of protonitazepyne. (A) Extracted ion chromatogram at m/z 409.2236 corresponding to the [M + H]+ ion of protonitazepyne from LC-HRMS data obtained following the analysis of plasma extract. (B) Experimental isotopic pattern of protonitazepyne and (C) MS/MS spectra of the [M + H]+ ion of protonitazepyne.
Figure 3 Analytical features of protonitazepyne. (A) Extracted ion chromatogram at m/z 409.2236 corresponding to the [M + H]+ ion of protonitazepyne from LC-HRMS data obtained following the analysis of plasma extract. (B) Experimental isotopic pattern of protonitazepyne and (C) MS/MS spectra of the [M + H]+ ion of protonitazepyne.CC BY · PubMed Central
Figure 4 Molecular network of protonitazene metabolites. Molecular network was built using the LC-HRMS data from both plasma and urine extracts. (A) Overview of the cluster of protonitazene metabolites. MS/MS spectra of the [M + H]+ ion of (B) OH-Protonitazene, (C) N-Desethyl Protonitazene, and (D) N-Desethyl OH-Protonitazene.
Figure 4 Molecular network of protonitazene metabolites. Molecular network was built using the LC-HRMS data from both plasma and urine extracts. (A) Overview of the cluster of protonitazene metabolites. MS/MS spectra of the [M + H]+ ion of (B) OH-Protonitazene, (C) N-Desethyl Protonitazene, and (D) N-Desethyl OH-Protonitazene.CC BY · PubMed Central
Figure 5 Annotation of protonitazepyne metabolite. (A) Extracted ion chromatogram at m/z 441.2131 corresponding to the [M + H]+ ion of protonitazepyne acid from LC-HRMS data obtained following the analysis of a urine extract. (B) MS/MS spectra of the [M + H]+ ion of protonitazepyne acid. (C) Proposed fragmentation pattern of protonitazepyne.
Figure 5 Annotation of protonitazepyne metabolite. (A) Extracted ion chromatogram at m/z 441.2131 corresponding to the [M + H]+ ion of protonitazepyne acid from LC-HRMS data obtained following the analysis of a urine extract. (B) MS/MS spectra of the [M + H]+ ion of protonitazepyne acid. (C) Proposed fragmentation pattern of protonitazepyne.CC BY · PubMed Central
Figure 6 Relative abundance of protonitazene metabolites in urine and plasma. (A) Area under the curve of protonitazene and its demethylated metabolites in plasma and urine. (B) Relative abundance in the urine of protonitazene metabolites based on the area under the curve of the chromatographic peak.
Figure 6 Relative abundance of protonitazene metabolites in urine and plasma. (A) Area under the curve of protonitazene and its demethylated metabolites in plasma and urine. (B) Relative abundance in the urine of protonitazene metabolites based on the area under the curve of the chromatographic peak.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 14

Metadata

Authors
Magny, R., Schiestel, T., M’Rad, A., Lefrère, B., Raphalen, J.-H., Ledochowski, S., Labat, L., Mégarbane, B., & Houzé, P.
Affiliations
  • Inserm (FR)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Hôpital Necker-Enfants Malades (FR)
  • Service de Réanimation Polyvalente, Médipôle Lyon-Villeurbanne, Ramsay Santé, 69100 Villeurbanne, France
Corresponding author
Magny, Romain
Venue
Metabolites
Publisher
MDPI AG
Published
2025-06-05
Volume
15
Issue
6
Pages
371
ISSN
2218-1989 (ISSN-L)
OpenAlex
W4411045819
Cited by
14
References
41
Citations by year
2026: 9 · 2025: 5
FWCI
7.14
Type
journal article
Language
en
Open access
Locations
  • Metabolites (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
  • Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Keywords
nitazenes, synthetic opioids, opioid toxicity, drug metabolism, phase I and phase II metabolites, glucuronidation, molecular network analysis, naloxone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of the Metabolic Profiles Associated with Protonitazene and Protonitazepyne in Two Severe Poisonings. https://app.cochat.ai/papers/10.3390/metabo15060371
The paper
Magny, R., Schiestel, T., M’Rad, A., Lefrère, B., Raphalen, J.-H., Ledochowski, S., Labat, L., Mégarbane, B., & Houzé, P. (2025). Comparison of the Metabolic Profiles Associated with Protonitazene and Protonitazepyne in Two Severe Poisonings. Metabolites. https://doi.org/10.3390/metabo15060371

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.